Aequus Pharmaceuticals Stock Probability of Future OTC Stock Price Finishing Under 0.0065
| AQSZF Stock | USD 0.01 0 18.18% |
Aequus |
Aequus Pharmaceuticals Target Price Odds to finish below 0.0065
The tendency of Aequus OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move below current price in 90 days |
| 0.01 | 90 days | 0.01 | about 20.34 |
Based on a normal probability distribution, the odds of Aequus Pharmaceuticals to move below current price in 90 days from now is about 20.34 (This Aequus Pharmaceuticals probability density function shows the probability of Aequus OTC Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon Aequus Pharmaceuticals has a beta of -0.68. This suggests as returns on the benchmark increase, returns on holding Aequus Pharmaceuticals are expected to decrease at a much lower rate. During a bear market, however, Aequus Pharmaceuticals is likely to outperform the market. Additionally Aequus Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Aequus Pharmaceuticals Price Density |
| Price |
Predictive Modules for Aequus Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Aequus Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Aequus Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Aequus Pharmaceuticals is not an exception. The market had few large corrections towards the Aequus Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Aequus Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Aequus Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.76 | |
β | Beta against Dow Jones | -0.68 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | -0.11 |
Aequus Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Aequus Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Aequus Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Aequus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Aequus Pharmaceuticals has high historical volatility and very poor performance | |
| Aequus Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Aequus Pharmaceuticals has accumulated 26.09 K in total debt with debt to equity ratio (D/E) of 1.39, which is about average as compared to similar companies. Aequus Pharmaceuticals has a current ratio of 0.76, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Aequus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aequus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aequus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aequus to invest in growth at high rates of return. When we think about Aequus Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 2.71 M. Net Loss for the year was (1.81 M) with profit before overhead, payroll, taxes, and interest of 2.69 M. | |
| Aequus Pharmaceuticals has accumulated about 1.39 M in cash with (1.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 15.0% of Aequus Pharmaceuticals shares are held by company insiders |
Aequus Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Aequus OTC Stock often depends not only on the future outlook of the current and potential Aequus Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Aequus Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 132.6 M |
Aequus Pharmaceuticals Technical Analysis
Aequus Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Aequus OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Aequus Pharmaceuticals. In general, you should focus on analyzing Aequus OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
Aequus Pharmaceuticals Predictive Forecast Models
Aequus Pharmaceuticals' time-series forecasting models is one of many Aequus Pharmaceuticals' otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Aequus Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about Aequus Pharmaceuticals
Checking the ongoing alerts about Aequus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Aequus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Aequus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Aequus Pharmaceuticals has high historical volatility and very poor performance | |
| Aequus Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Aequus Pharmaceuticals has accumulated 26.09 K in total debt with debt to equity ratio (D/E) of 1.39, which is about average as compared to similar companies. Aequus Pharmaceuticals has a current ratio of 0.76, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Aequus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aequus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aequus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aequus to invest in growth at high rates of return. When we think about Aequus Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 2.71 M. Net Loss for the year was (1.81 M) with profit before overhead, payroll, taxes, and interest of 2.69 M. | |
| Aequus Pharmaceuticals has accumulated about 1.39 M in cash with (1.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 15.0% of Aequus Pharmaceuticals shares are held by company insiders |
Other Information on Investing in Aequus OTC Stock
Aequus Pharmaceuticals financial ratios help investors to determine whether Aequus OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Aequus with respect to the benefits of owning Aequus Pharmaceuticals security.